论文部分内容阅读
目的探讨噻托溴铵在尘肺病合并慢性阻塞性肺疾病患者治疗中的临床价值。方法选取2015年4月至2016年4月沈阳急救中心收治的110例尘肺病合并慢性阻塞性肺疾病患者作为研究对象,按照随机数字表法将其分为观察组与对照组,各55例。对照组患者给予常规对症治疗,观察组患者在此基础上采用噻托溴铵进行治疗,比较两组患者的临床疗效、治疗前后肺功能及不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的用力肺活量(FCV)、第1秒钟用力呼气容积(FEV1)、肺活量占预计值的百分比(FEV1%)、呼气峰流速(PEF)、FEV1/FCV均明显高于对照组,差异均有统计学意义(均P<0.05)。结论在尘肺病合并慢性阻塞性肺疾病患者的临床治疗过程中,采用噻托溴铵进行治疗临床效果显著,可有效改善患者肺功能,且安全性较高。
Objective To investigate the clinical value of tiotropium in the treatment of pneumoconiosis patients with chronic obstructive pulmonary disease. Methods A total of 110 patients with pneumoconiosis and chronic obstructive pulmonary disease admitted to Shenyang Emergency Center from April 2015 to April 2016 were selected as study subjects and divided into observation group and control group according to the random number table method, each with 55 cases. Patients in the control group were given conventional symptomatic treatment. Patients in the observation group were treated with tiotropium on the basis of the above data. The clinical efficacy, the pulmonary function and adverse reactions before and after treatment were compared between the two groups. Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). After treatment, the forced vital capacity (FCV), forced expiratory volume 1 second (FEV1) (FEV1%), peak expiratory flow (PEF) and FEV1 / FCV of the control group were significantly higher than those of the control group (all P <0.05). Conclusions In the clinical treatment of patients with pneumoconiosis complicated with chronic obstructive pulmonary disease, tiotropium bromide has a significant clinical effect, which can effectively improve pulmonary function and have higher safety.